Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 6/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31222758 | 0.90 | PRMT5 (0.32) | PRMT5WDR77ADORA1PDE1APDE1B | |
| SCHEMBL25581297 | 0.86 | PRMT5 (0.36) | PRMT5WDR77ADORA1PDE1APDE1B | |
| SCHEMBL31222760 | 0.82 | ADORA1 (0.32) | ADORA1PDE1APDE1BPDE3BPDE1C | |
| SCHEMBL31222747 | 0.82 | GRM2 (0.35) | PRMT5WDR77ADORA1PDE1APDE1B | |
| SCHEMBL25581275 | 0.74 | ADORA1 (0.38) | PRMT5WDR77ADORA1PDE1APDE1B | |
| SCHEMBL27002444 | 0.73 | AR (0.34) | PRMT5WDR77ADORA1PDE1APDE1B | |
| SCHEMBL25581278 | 0.73 | ADORA1 (0.33) | PRMT5WDR77ADORA1PDE1APDE1B | |
| SCHEMBL31376007 | 0.71 | PRMT5 (0.56) | PRMT5WDR77 | |
| SCHEMBL30833175 | 0.70 | PRMT5 (0.43) | PRMT5WDR77 | |
| SCHEMBL25208948 | 0.69 | PRMT5 (0.58) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408088-A1 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4442680-A1 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Abbisko Therapeutics Co., Ltd. (CN) | 2024-10-09 | — | — | EP | disclosed |
| WO-2023098439-A1 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 上海和誉生物医药科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408088-A1 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | PRMT5, PRMT1, PRMT8 | PRMT5 1/4885WDR77 38/4885ADORA1 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.